Tiger Brokers

BUZZ-Street View: Eli Lilly's momentum is building despite pricing pressure

Reuters
Feb 05
BUZZ-Street View: Eli Lilly's momentum is building despite pricing pressure

** Eli Lilly LLY.N forecast strong growth for 2026 on Wednesday on the back of surging demand for obesity drugs, shaking off pricing pressures that sunk rival Novo Nordisk's NOVOb.CO outlook

** Median PT of 33 brokerages covering the stock is $1205 - data compiled by LSEG

ORFORGLIPRON LAUNCH ON THE HORIZON

** BMO ("outperform," PT: $1300) says Lilly is well positioned for 2026 and beyond; co's momentum is building into the new year with its incretin business continuing to drive significant growth despite pricing headwinds

** J.P. Morgan ("overweight," PT: $1300) sees rapid uptake among consumers for orforglipron especially among the "less-penetrated overweight population as well as among those wanting non-injectable options"

** Truist Securities ("buy," PT: $1281) says LLY has a strong growth year ahead fueled by the expansion of Mounjaro and launch of orforglipron in the U.S.

** Morningstar (fair value: $870) says Lilly's orforglipron has an upper hand internationally over rival Novo's Wegovy given its ease of manufacturing; adds orforglipron's launch in the U.S. in 2026 and in 2027 internationally will be a major catalyst for shares

(Reporting by Kanchana Chakravarty in Bengaluru)

((Kanchana.Chakravarty@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10